Abstract
GEN EdgeVol. 5, No. 1 TopicsPhoreMost Achieves Target Discovery Milestone with Boehringer IngelheimUsing the targets found by PhoreMost, Boehringer Ingelheim will now develop potential new treatments, which could result in additional success-based pre-clinical, clinical, and commercial milestone paymentsJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:6 Jan 2023https://doi.org/10.1089/genedge.5.1.05AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.PhoreMost Achieves Target Discovery Milestone with Boehringer Ingelheim.GEN Edge.Jan 2023.21-23.http://doi.org/10.1089/genedge.5.1.05Published in Volume: 5 Issue 1: January 6, 2023PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
